ASND (Ascendis Pharma AS) Short-Term Debt: $590 Mil (As of Mar. 2026)


ASND Ascendis Pharma AS ASND
37 GF Score
Price $277.18
! 5 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Short-Term Debt?

Ascendis Pharma AS ASND +3.82% 37 Short-Term Debt is $590 Mil as of Mar. 2026. GuruFocus rates ASND with a GF Score™ of 37/100. The stock has 5 warning signs investors should review.

Ascendis Pharma AS's Short-Term Debt for the quarter that ended in Mar. 2026 was $590 Mil.

Ascendis Pharma AS's quarterly Short-Term Debt increased from Sep. 2025 ($566 Mil) to Dec. 2025 ($570 Mil) and increased from Dec. 2025 ($570 Mil) to Mar. 2026 ($590 Mil).

Ascendis Pharma AS's annual Short-Term Debt increased from Dec. 2023 ($459 Mil) to Dec. 2024 ($515 Mil) and increased from Dec. 2024 ($515 Mil) to Dec. 2025 ($570 Mil).

Ascendis Pharma AS Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Ascendis Pharma AS Short-Term Debt Related Terms

Ascendis Pharma AS Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Short-Term Debt Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.90 437.48 459.40 514.70 569.71

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 529.69 533.27 566.06 569.71 590.24
ASND
37GF Score
Ascendis Pharma AS ASND
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $590 Mil mean?
Ascendis Pharma AS (ASND) has a Short-Term Debt of $590 Mil as of Mar. 2026.
Is Ascendis Pharma AS's Short-Term Debt too high?
Ascendis Pharma AS's current Short-Term Debt is $590 Mil. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Short-Term Debt compare to JAZZ and BBIO?
Ascendis Pharma AS's Short-Term Debt of $590 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Ascendis Pharma AS's current Short-Term Debt is $590 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current Short-Term Debt of $590 Mil. The current Short-Term Debt is $590 Mil. Ascendis Pharma AS's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Short-Term Debt is $590 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges A1SN34:Brazil
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for ASND

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$277.18
Price